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Abstract
Introduction: Adherence to therapy is one of the basic preconditions of successful treatment of asthma and COPD. Unfortunately, 
many patients take their medication incorrectly. The aim of this study was to assess doctors’ knowledge of this phenomenon, 
including interventions able to improve patient adherence.
Materials and methods: It was a questionnaire-based survey conducted among convenience sample of Polish physicians treating 
asthma and COPD. 
Results: One hundred and sixty one physicians, mainly specialists in allergology (44.1%) and pulmonology (37.3%) took part in the 
study. According to participants, asthma patients took on average 65.4 ± 17.1% of doses of prescribed drugs, whereas COPD pa-
tients — 61.6 ± 24.2%. Over half of respondents claimed that during the first year of treatment, no more than 20% of asthma and 
COPD patients discontinue their therapy. Survey participants pointed at patients discourage (41.6%) and lack of knowledge about 
disease (19.3%) as the main reasons for discontinuation of therapy. Almost 2/3 of participants (65.8%) claimed that they could 
recognize non-adherence in their patients. Prescribing combination inhaled drugs (72.7%), drugs with infrequent dosing (63.4%), 
and affordable ones (53.4%) were the most common interventions aimed at improving adherence provided by respondents.
Conclusions: Survey participants were aware of the phenomenon of non-adherence in patients with asthma and COPD, but un-
derestimated the real prevalence and seriousness of it. They also overestimated their ability to recognise non-adherence in their 
patients. Therefore, not necessarily they may obtain better adherence in their asthma and COPD patients. These results point 
at the issues which should be addressed in pre- and postgraduate education of physicians treating chronic airways conditions.
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Introduction
Non-adherence to medical recommendations 
consists in various deviations made by patients 
from treatment schedule that had been agreed 
with health professionals [1]. Due to high preva-
lence and serious consequences of the phenome-
non, WHO has considered the problem “a global 
issue of crucial significance” [2]. As it has been 
repeatedly shown, at least 50% of patients with 
chronic illnesses do not adhere to prescribed 
therapy. According to the studies conducted in 
Poland, the phenomenon is even more prevalent 
among Poles: in the group of 63,000 study sub-
jects suffering from different chronic diseases, 
as many as 83.8% admitted to non-adherence to 
prescribed regimen [3]. 
Non-adherence to recommended therapy re-
duces the effectiveness of treatment and increases 
the costs of medical care [2]. Therefore, of impor-
tance is the awareness of factors that promote 
non-adherence, and the delivery of interventions 
that increase patient adherence to therapy, parti-
cularly in the case of most frequent, so the most 
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important from the public health view, chronic 
illnesses. Such diseases undoubtedly include 
asthma and chronic obstructive pulmonary di-
sease (COPD), for they affect over 300 million 
people worldwide [4, 5].
Non-adherence to prescribed therapy in 
asthma results in worse disease control and more 
frequent exacerbations. In addition, it leads to 
poor patients’ quality of life, a greater demand 
for medical services, including more frequent 
hospitalizations, and increased mortality. It also 
constitutes a vital source of costs incurred by 
health care systems. Non-adherence to therapy in 
case of COPD brings about similar effects, being 
one of the main reasons for ineffective treatment 
of the disease and related costs [6–10]. 
Doctors do have their role in ensuring that 
patients adhere to prescribed regimen. On the one 
hand, it is important to undertake routine actions 
aimed at preventing non-adherence to prescribed 
drugs. Such actions include among the others 
providing patients with information about objec-
tives and methods of treatment in a manner that 
would create in them the motivation for starting 
and continuing the therapy. On the other hand, 
there is a need to actively search for the cases of 
non-adherence to medical regimen in order to 
promptly deliver appropriate interventions [6]. 
Although the problem in question is of higher 
importance, there are merely few studies concer-
ning the awareness of doctors and their actions 
aimed at enhancing patients adherence during 
asthma and COPD therapy [8, 11]. The studies car-
ried out in Poland have found that primary health 
providers are not fully aware of the spread of the 
problem, and do not know the interventions that 
could limit the range of the phenomenon [12]. The 
objective of the study was an attempt to assess 
the awareness of non-adherence to prescribed 
therapy of health professionals who treat patients 
with asthma and COPD in Poland, and to learn 
the interventions they deliver to improve the 
regularity of treatment in this group of patients.
Material and methods
The study was based on an anonymous and 
voluntary questionnaire survey conducted among 
doctors treating patients with asthma and COPD. 
The original questionnaire constructed for this 
study (see Annex 1) included 10 questions con-
cerning the issues related to patients adherence 
to asthma and COPD therapy, and 3 questions 
about the subjects’ characteristic (age, sex, and 
specialist medical training). The questionnaire 
was made available at a dedicated surveying 
website (SurveyMonkey). The information about 
the study along with the link to the questionnaire 
was made available to doctors who registered 
for the scientific conference on allergology and 
pulmonology (18th Scientific and Training Con-
ference “Advances in Allergology and Pulmono-
logy”, Cracow, 2012). The experimental part of 
the study was conducted between 1 June and 5 
November 2012.
As many physicians who took the survey had 
more than one specialisation, they were assigned 
post factum to one of three groups:
 — ”lung disease specialists taking care of chil-
dren” — the group included doctors who 
apart from specialisation in allergology or 
lung diseases, took paediatrics as one of their 
specialist trainings,
 — ”lung disease specialists not taking care of 
children” — the group included doctors who 
had at least one of the following specialisa-
tions: allergology, lung diseases (pulmonolo-
gy), but not paediatrics,
 — ”others” — the group included all remaining 
doctors who answered to the question about 
specialisation.
Data collected in online survey were trans-
ferred to a special database, and then analysed 
using standard methods of descriptive analysis. 
The results were presented as percentage of all 
study subjects, unless otherwise specified. Diffe-
rences between the answers to questions given by 
“lung disease specialists taking care of children” 
and “lung disease specialists not taking care of 
children” were assessed with the help of chi2 test 
(for qualitative variables) and Kruskal-Wallis test 
(for quantitative variables), assuming p < 0.05 as 
statistically significant. 
Results
161 doctors, including 115 women (71.4%) 
participated in the study. The mean age of the 
respondents was 51.2 ± 8.6 years. Doctors with 
specialisation in allergology (44.1%) and lung 
diseases (37.3%) predominated. 14 persons (8.7% 
of the subjects) have not provided information 
on their specialisation, and this group has not 
been taken into account in statistical calculations 
concerning correlations between the chosen pa-
rameters concerning specialisation. Detailed char-
acteristic of the subjects is presented in Table 1.
According to the respondents, the percent-
age of prescribed doses taken by their patients 
averaged 65.4 ± 17.1% for patients with asthma, 
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and 61.6 ± 24.2% for COPD patients. Over half 
of the study subjects have claimed that therapy 
of asthma and COPD is stopped within the first 
12 months of treatment by not more than 20% 
of patients (52.2% and 50.9%, respectively). The 
proportion of patients who stop therapy within 
the first 12 months the most often was assessed 
at 10–20% among asthmatic patients (36.6% of 
answers), and among COPD patients — most 
often at 10% (27.3% of answers) (Fig. 1 and 2). 
More than 1/5 of the doctors surveyed (21.7%) 
were not able to give the proportion of patients 
who stopped treatment of COPD within the first 
year of therapy — which was probably related to 
the lack of personal experience with this group of 
patients (25 doctors out of 36 subjects who gave 
such an answer, belonged to the group of “lung 
disease specialists taking care of children”).
According to the respondents, the main 
causes of stopping the therapy by asthma and 
COPD patients were first of all discouragement 
of patients (41.6%), insufficient knowledge about 
the disease (19.3%), and less frequently — lack of 
noticeable for the patient effects of treatment, and 
the price of drugs (6.2% and 5.6%, respectively, 
Figure 3). Whereas the proportion of patients with 
Table 1. Characteristics of the study subjects
n %
Age (years) Mean (± standard deviation) 51.2 (± 8.6)
Sex Female
Male
No data available
115
34
12
71.4
21.1
7.5
Specialisation* Allergology
Lung diseases
Paediatrics
General medicine
Internal diseases
Others
No data available
71
60
7
5
3
1
14
44.1
37.3
4.3
3.1
1.9
0.6
8.7
The study group# Lung disease specialists taking care of children
Lung disease specialists not taking care of children
Others
No data available
54
85
8
14
Total 161 100.0
*specialisation indicated by the respondent as main (first) specialisation; #the study group was classified ex post basing on information about specialisations, see 
“Material and methods”
Figure 1. The proportion of patients who, according to the study subjects, stop their treatment for asthma within 12 months since diagnosis. The 
proportions were calculated for all study subjects (n = 161). The diagram does not include the group “no answer available” (n = 9)
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Figure 2. The proportion of patients who, according to the study subjects, stop their treatment for COPD within 12 months since diagnosis. The 
proportions were calculated for all study subjects (n = 161). The diagram does not include the group “no answer available” (n = 9)
Figure 3. Main reasons for discontinuation of treatment for asthma and COPD according to the respondents. The proportions were calculated for 
all study subjects (n = 161). The diagram does not include the group “no answer available” (n = 9)
asthma and COPD that at least once did not buy 
medication due to its price within the preceding 
12 months was quite small: in opinion of 42.9% of 
the respondents such a situation occurred in less 
than 10% of patients, and according to 31.1% of 
the respondents — in 10–50% of patients. Bare-
ly 4.3% of the respondents answered that such 
case could have happened among 50% or greater 
percentage of patients.
The doctors surveyed were also asked, wheth-
er they were able to recognise non-adherence to 
treatment in their patients. Nearly 2/3 of the 
respondents (65.8%) claimed that they could do 
so “in most of cases”, and 9.3% — “practically in 
every case”. Every fifth doctor declared that he/
she had difficulties in recognising non-adherence 
to therapy among their patients (18.6% were able 
to recognise non-adherence “in the minority 
of cases”, and barely 3.7% of the respondents 
admitted that they were not able to do so). Sim-
ilarly, the majority of respondents maintained 
that they asked their patients about adherence 
to treatment — 72.7% of respondents answered 
that they ask about it during each consultation, 
and merely 1.9% — that they seldom ask about 
it, and 1.2% — that they never ask about it. The 
respondents also declared that when they discov-
ered that recently ordered therapy was ineffective, 
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at first they took actions in order to assess and 
exclude possible problems related to regularity of 
treatment (61.5% of respondents listed it as the 
most frequently taken action), and the other most 
often taken interventions included: increasing 
dosage of medication, adding another drug to the 
therapy, and the exchange of the medication with 
another one from the same therapeutic group, in 
accordance with the guidelines (Figure 4).
Finally, the respondents were also asked to 
indicate interventions they made to improve their 
patients’ adherence to therapy. The most frequent 
actions were as follows: prescribing combination 
drugs (72.7% of respondents), choosing medica-
tion with infrequent administration (63.4%) and 
prescribing inexpensive drugs (53.4%).
The differences between the answers given 
by “lung disease specialists taking care of chil-
dren” and “lung disease specialists not taking care 
of children” that would meet the criteria of statis-
tical significance (p < 0.05) were not found. The 
exception was the assessment of the percentage 
of drugs taken by COPD patients: “lung disease 
specialists taking care of children” evaluated this 
percentage significantly lower than “lung disease 
specialists not taking care of children” (54.4 ± 
26.4% vs. 66.0 ± 22.0%, p < 0.01, respectively).
Discussion
Adherence to therapy in asthma and COPD 
treatment is of crucial importance for both indivi-
duals and the whole population. Non-adherence 
in these conditions is connected with patients’ 
poor quality of life, lower productivity, increased 
morbidity and mortality, and bigger demand for 
medical services and extra costs [13]. Therefore, 
it is important for doctors treating patients with 
chronic lungs diseases — pulmonologists, aller-
gologists, and general practitioners — to be aware 
of the magnitude of the problem, and be able to 
react accordingly.
However, the present study has shown that 
physicians overestimate degree to which patients 
adhere to prescribed regimen. Both the estimate 
of average percentage of drug doses taken by pa-
tients and of the percentage of patients who stop 
their treatment (numerous doctors believed that 
barely 10–20% of patients stop therapy during 
the first 12 months of treatment) were conside-
rably overstated. In many authors’ opinion, the 
majority of patients with chronic airways con-
ditions do not adhere to the treatment — as far 
as COPD is concerned, it applies to as many as 
60–80% of patients [14, 15]. Particularly serious 
consequences are related to complete disconti-
nuation of therapy. According to the literature, 
40% of COPD patients stop their treatment after 
30 days, and 70% of them discontinue it within 
the first 90 days from initiation [16]. The analysis 
of the regularity of treatment with inhaled drugs 
in Poland confirms these tendencies: according 
to observations, at least 40% of Polish patients 
discontinue therapy after 3 months of treatment 
for COPD, and for asthma — even 70% [17]. 
One of the possible explanations of this 
discrepancy is the fact that it may be difficult 
for doctors to accept that a considerable amount 
Figure 4. Interventions made by the doctors surveyed in case of ineffectiveness of the previously prescribed therapy (the respondents were to 
define the frequency of their interventions, from the most frequent to the least frequent)
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of their patients do not adhere to their instruc-
tions. It is contrary to what doctors can observe 
in everyday practice: the patients visit them and 
accept prescriptions. Therefore physicians tend 
to see the problem among other patients who are 
treated by the other healthcare professionals. This 
explains the fact that, as it has been found in the 
present study, “lung disease specialists taking 
care of children” — so having rare contact with 
COPD patients — expected that these patients 
stop therapy more often, compared to doctors 
who take care of these patients on a daily basis. 
A systematic review carried out recently has 
shown numerous reasons for which patients do 
not adhere to prescribed regimens [18]. In the case 
of asthma and COPD, some patients do not treat 
their disease seriously [19], some patients stop 
their therapy when symptoms disappear [20] or 
because they think that the therapy is too complex 
[21], others are afraid of possible adverse drug 
reactions, and that the drug will not work during 
subsequent exacerbation [22]. The evaluation 
of reasons for which patients stop treatment for 
asthma and COPD made by doctors participating 
in the present study was realistic. The most vital 
causes of non-adherence are discouragement of 
patients, in particular in the case of lack of visible 
effects of treatment, and insufficient knowledge 
about the disease. 
A significant role in non-adherence to me-
dical recommendations in Poland, especially in 
case of expensive medication, may be played by 
financial factors. Although essential drugs used 
in asthma and COPD are relatively inexpensive 
for the insured patient, some medication may 
pose financial problems to many (e.g. monthly 
therapy with tiotropium will cost the majority 
of patients more than PLN 40.00). Thus it may 
be assumed that the opinions of the respondents 
did not correspond perfectly with the range of 
the phenomenon — a survey conducted in 2012 
revealed that as many as 27% of Poles declared 
that they did not buy prescribed medication due 
to financial reasons [23]. 
More than 2/3 of the respondents believed 
that they were able to recognise non-adherence to 
treatment in the majority of their patients. Unfor-
tunately, as it has been proved on many occasions, 
doctors are not able to assess the degree of their 
patients’ adherence to therapy, even though they 
know and treat them for many years [24]. 
A definite majority of respondents declared 
that they ask their patients about the regularity of 
treatment at every visit. Although such method 
is easy and readily available, it is not a precise 
tool to assess adherence to treatment. Numerous 
studies have proved that information obtained 
from patients is biased due to their subjectivity. It 
happens frequently that patients, in order to satis-
fy their doctors, overestimate adherence to their 
therapy [25, 26]. To verify whether the patient 
adheres to treatment, it is possible to count taken 
doses, or check if he or she systematically buys 
prescribed medication. Another approach may 
be based on controlling the patient’s biological 
markers or using electronic drug monitoring [27].
Despite all these limitations, the fact that 
doctors often ask their patients about their adhe-
rence to therapy is encouraging, as effective 
communication between the doctor and patient 
is crucial for proper adherence to medical re-
commendations [11, 26]. The fact of asking 
about adherence puts an emphasis on the role 
of treatment regularity in successful therapy, 
also it additionally motivates patients to adhere 
to prescribed regimen. Furthermore, it is a good 
starting point for the identification of barriers 
to adherence and elimination thereof [28]. The 
whole process may make use of typology drawn 
up by Rand [29], who described three types of 
non-adherence to prescribed regimen and propo-
sed specific solutions to them. According to this 
typology, an “irregular patient” understands the 
therapy, accepts it but does not adhere to it due to 
too tight day schedule, forgetfulness, lack of atten-
tion for small matters. In such a case, simplifying 
the drug regimen and monitoring medication 
adherence by third parties may be helpful. An 
“unaware patient” unintentionally misinterprets 
treatment instructions, e.g. because of language 
barriers, cultural differences or other ailments 
(dementia, depression, worries). Education and 
written instructions regarding the drug regimen 
may be the most helpful for such patients. The 
third type of patient is called “intelligent” — it 
characterises persons who intentionally do not 
take drugs due to their negative beliefs regarding 
their efficacy, adverse effects and toxicity. In 
such a case, good doctor-patient communication 
presenting benefits related to the therapy may 
positively influence adherence.
What is important, in case of non-adherence, 
the respondents declared that they were focusing 
on the improvement of its regularity, and not the 
modification of the therapy. It is vital because the 
choice of effective medication in the therapy of 
asthma and COPD is not particularly wide, and 
together with the recommendations of the clinical 
practice guidelines, it does not allow to radically 
change the therapy. Unfortunately, the compari-
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son of these declarations with the results of the 
analysis of nationwide database of pharmacy 
claims leaves no doubts as to the fact that such 
interventions are ineffective, taking into account 
that not more than 13% of asthmatic patients 
and 21% of COPD patients take inhaled drugs 
systematically over the period of 12 months, on 
average [17].
Improved regularity of treatment is vital, 
taking into consideration that adherence to the-
rapy in asthma and COPD is poorer than in other 
chronic conditions [30]. The most popular in-
tervention to enhance adherence declared by the 
doctors interviewed was prescribing combination 
inhaled drugs. Their decision based on rational 
assumptions, for there are studies confirming the 
effectiveness of improved adherence to medical 
recommendations with combination inhalers, 
compared to the same drugs taken separately, both 
in asthma [31] and COPD [32]. However, such 
a correlation has not been found in the Polish 
setting: the already mentioned analysis of natio-
nal database of pharmacy claims has not shown 
more regular or persistent treatment of asthma 
or COPD by patients taking combination drugs, 
compared to those using inhaled betamimetics 
and corticosteroids in two separate inhalers [17].
In order to improve adherence to therapy, the 
respondents were also choosing other interven-
tions of proven effectiveness such as prescribing 
medication of infrequent dosing. Less frequent 
dosing does improve adherence to treatment, both 
in asthma and COPD [33, 34]. In general, it has 
been observed that the less frequent administra-
tion of drugs, the better adherence to prescribed 
regimen, and this rule applies also to drugs ad-
ministered once and twice a day [35].
The present study has its obvious limitations. 
The way in which the study group has been cho-
sen does not guarantee that it is representative. 
According to the Central Statistical Office of Po-
land [Główny Urząd Statystyczny], 1,384 doctors 
with specialisation in lung diseases worked in 
2012 in Poland [36]. Approximately 9% of them 
participated in the present study, which may be 
satisfying taking into account survey-based form 
of the study. In addition, the fact that the study 
included doctors participating in the scientific and 
training conference, could impact on deeper, than 
in most of doctors, awareness of the study subject.
Conclusions
The doctors interviewed were aware of 
non-adherence to medical recommendations 
of patients with asthma and COPD, but they 
underestimated its real prevalence. They also 
undervalued the financial side of the problem. On 
the other hand, they overestimated their ability 
to recognise non-adherence to treatment in their 
patients and they took remedial actions that do 
not guarantee a real improvement in adherence. 
These results indicate the issues that should be 
approached in pre- and postgraduate education 
of health professionals dealing with therapy of 
asthma and COPD. 
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Annex 1. The questionnaire used in the study
We kindly ask you to complete a short, anonymous questionnaire that will allow to know 
the problems You encounter during Your everyday practice with patients with ASTHMA 
and COPD.
 — What do You usually do in the case of ineffectiveness of recent, relatively newly prescribed therapy? 
Please arrange the answers from the most frequent to the least frequent interventions, assigning 
to them the numbers from 1 to 4 (1 — the most frequent interventions, 4 — the least frequent 
interventions).
• I increase the dose of the administered drug/drugs (if possible)
• I change the drug to another one from the same or another therapeutic group, according to the 
guidelines
• I add a subsequent drug that is indicated as complementary/additional treatment for the disease
• I make interventions that allow to assess and eliminate possible problems of the patient’s adhe-
rence to treatment
 — Are you able to recognise the patient’s non-adherence to the therapy?
• Non, I am not
• I am able to recognise it in the minority of cases
• I am able to recognise it in the majority of cases
• I am able to recognise it almost in all cases
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 — Do You ask Your patients about adherence to their treatment?
• Non, never
• Rarely
• Often
• I do, almost at every visit
 — What percentage of drug doses do Your patients with asthma take?
 — What percentage of drug doses do Your patients with COPD take?
 — What percentage of Your patients stop treatment of ASTHMA within 12 months since diagnosis?
• Less than 10%
• 10–20%
• 20–50%
• 50–80%
• 80–90%
• More than 90%
• I don’t know
 — What percentage of Your patients stop treatment of COPD within 12 months since diagnosis?
• Less than 10%
• 10–20%
• 20–50%
• 50–80%
• 80–90%
• More than 90%
• I don’t know
 — What is in your opinion the main reason for stopping treatment by patients with asthma and COPD?
• Adverse effects of drugs
• Price of drugs
• The frequency of drugs’ administration
• Lack of noticeable to the patient effects of treatment
• Reluctance of patients to treat systematically
• Inadequate patients’ awareness of the disease and the treatment conducted
• Others
 — What percentage of Your patients with ASTHMA and COPD did not buy drugs within the previous 
12 months at least once due to the price of the drugs?
• Less than 10%
• 10–50%
• 50–90%
• More than 90%
• I don’t know
 — Do You use any methods to enhance Your asthmatic and COPD patients’ adherence to the therapy? 
(many options are possible)
• I try to prescribe drugs with short names
• I try to prescribe inexpensive drugs
• I try to prescribe combination inhaled drugs including more than one active substance in one dose
• I try to prescribe inhaled drugs not including glucose
• I try to prescribe drugs with infrequent dosing
Please, complete with Your personal data
• Age
• Sex
• Woman
• Man
• Specialisation
• Thank You for completing the questionnaire
